BBC Performance — Virtus LifeSci Biotech Clinical Trials ETF
Data updated: 2026-09-29
BBC returned +26.24% year to date and +129.40% over one year to Jul 2026. Annualised returns are +27.67% over 3 years and +2.60% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $208, against $137 for the category, and to $229 over one year, against $137. Volatility over the past three years was 36.04% a year. In the 12 months to Jul 2026 the fund took in a net $11.7M, and assets reached $46.39M.
BBC Growth of $100
What $100 invested in Virtus LifeSci Biotech Clinical Trials ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | BBC | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $229 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $208 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $114 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $181 | $183 |
BBC Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +26.24% |
| 1 year | +129.40% |
| 3 years (annualised) | +27.67% |
| 5 years (annualised) | +2.60% |
BBC Annual Returns
Calendar-year total returns of Virtus LifeSci Biotech Clinical Trials ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +26.24% |
| 2025 | +63.80% |
| 2024 | −0.91% |
| 2023 | −1.64% |
| 2022 | −35.38% |
| 2021 | −22.35% |
| 2020 | +30.82% |
| 2019 (Aug–Dec) | +36.66% |
BBC Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5.6% | +3.9% | −1.7% | +5.3% | +1.6% | +18.0% | −7.3% | — | — | — | — | — |
| 2025 | −4.1% | −11.5% | −13.5% | +8.9% | −5.1% | +6.0% | +12.2% | +5.1% | +20.4% | +18.0% | +16.8% | +4.2% |
| 2024 | +3.5% | +18.7% | −3.0% | −10.6% | +1.8% | −4.8% | +14.3% | −3.0% | −0.4% | +1.4% | −3.1% | −11.6% |
| 2023 | +10.9% | −9.6% | −12.2% | +4.8% | +5.8% | −1.5% | +0.7% | −11.2% | −8.5% | −9.1% | +9.9% | +25.1% |
| 2022 | −22.4% | −4.9% | −2.0% | −20.9% | −12.5% | +12.3% | +11.1% | +5.3% | −3.2% | +5.4% | −1.9% | −1.7% |
| 2021 | +5.8% | +3.4% | −5.6% | −1.2% | −5.2% | +4.0% | −11.6% | +8.0% | −4.3% | −3.1% | −8.4% | −5.0% |
| 2020 | −6.7% | −3.1% | −14.5% | +19.9% | +16.8% | +5.0% | −10.0% | +4.3% | −3.9% | −0.1% | +20.7% | +5.7% |
| 2019 | — | — | — | — | — | — | — | −4.6% | −10.1% | +10.7% | +21.8% | +18.2% |
BBC Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 36.04%
- 3-year Sharpe ratio: 0.64 (vs 4.5% risk-free rate)
- Best month: +25.14% (Dec 2023)
- Worst month: −13.52% (Mar 2025)
BBC Fund Flows
Monthly money in and out of Virtus LifeSci Biotech Clinical Trials ETF, from SEC Form N-PORT.
- 12-month net flow: $11.7M
- 12-month gross sales (incl. reinvestments): $32.0M
- Sales ÷ redemptions: 1.58×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $5.2M | $5.1M | $161K |
| Jun 2026 | $0 | $2.1M | −$2.1M |
| May 2026 | $9.1M | $2.1M | $7.0M |
| Apr 2026 | $2.3M | $2.1M | $175K |
| Mar 2026 | $0 | $2.0M | −$2.0M |
| Feb 2026 | $2.0M | $2.0M | −$26K |
| Jan 2026 | $1.9M | $0 | $1.9M |
| Dec 2025 | $9.7M | $3.8M | $5.9M |
| Nov 2025 | $1.8M | $0 | $1.8M |
| Oct 2025 | $0 | $0 | $0 |
| Sep 2025 | $0 | $1.2M | −$1.2M |
| Aug 2025 | $0 | $0 | $0 |
BBC Assets Under Management
Net assets of Virtus LifeSci Biotech Clinical Trials ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $46.39M |
| 2026-04-30 | $37.33M |
| 2026-01-30 | $36.75M |
| 2025-10-31 | $20.99M |
| 2025-07-31 | $15.15M |
| 2025-04-30 | $15.34M |
| 2025-01-31 | $6.90M |
| 2024-10-31 | $11.32M |
| 2024-07-31 | $11.54M |
| 2024-04-30 | $10.42M |
| 2024-01-31 | $10.13M |
| 2023-10-31 | $8.04M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.